Clinical Effect of Ilaprazole Enteric-Coated Tablets in Patients with Peptic Ulcer

Objective: To discuss the actual effect of ilaprazole enteric-coated tablets in the treatment of peptic ulcer patients. Methods: 200 peptic ulcer patients who received treatment from January to December 2023 were selected as the study sample, and all patients were randomly and evenly divided into the study group (n = 100) and the control group (n = 100), and the serum inflammatory factors and the disappearance time of symptoms were compared. Results: After treatment, the serum inflammatory factors in the observation group were better than those in the control group, and the time of belching and burning sensation in the observation group was shorter than that in the control group, all of which were statistically significant (P Conclusion: Ilaprazole enteric-coated tablets in the treatment of peptic ulcer have a good effect and can effectively improve the symptoms of patients with clinical signs, with reference significance.

Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction

Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized.

The Therapeutic Effect of Biling Weitong Granules Combined with Oryz-Aspergillus Enzyme and Pancreatin Tablet on Reflux Esophagitis with Functional Dyspepsia

Objective:To investigate the therapeutic effect of Biling Weitong Granules combined with oryz-aspergillus enzyme and pancreatin tablets on patients with reflux esophagitis with functional dyspepsia.Methods:Sixty patients diagnosed with reflux esophagitis with functional dyspepsia who were admitted to the Affiliated Hospital of Hebei University between June 2020 and June 2023 were selected and divided into two groups:the control group and the observation group,each consisting of 30 cases.The control group received oryz-aspergillus enzyme and pancreatin tablets only,while the observation group received Biling Weitong Granules in addition to the tablets.The clinical efficacy,Chinese medicine syndrome points,esophageal kinetic indexes,gastrointestinal hormone levels,and therapeutic safety of both groups were evaluated.Results:The total efficiency of the observation group reached 93.33%,significantly higher than the 73.33%of the control group(P<0.05).After treatment,patients in the observation group exhibited significantly lower scores for Chinese medicine symptoms such as early satiety,belching,abdominal distension,abdominal pain,and loss of appetite compared to the control group(P<0.05).Furthermore,the observation group showed significantly higher upper esophageal sphincter pressure,lower esophageal sphincter pressure,and distal esophageal contraction scores compared to the control group(P<0.05).Additionally,levels of gastric motility hormone,vasoactive intestinal peptide,and gastrin were significantly higher in the observation group compared to the control group(P<0.05).Throughout the treatment period,there was no significant difference in the incidence of adverse reactions between the two groups,indicating comparable safety of the two treatment modalities(P>0.05).Conclusion:The combination of Biling Weitong Granules with oryz-aspergillus enzyme and pancreatin tablets demonstrates significant efficacy in the treatment of reflux esophagitis with functional dyspepsia,with a better safety profile.This finding warrants further clinical promotion.

Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan. Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable cases are relatively uncommon because of hepatic function reserve and/or an advanced stage at presentation. Several modalities, such as transcatheter arterial chemoembolization, percutaneous ethanol injection, microwave coagulation therapy and radiofrequency ablation are reportedly useful in treating patients with non-resectable disease. However, unfortunately, many HCC patients have tumor recurrence. The overall prognosis of patients with HCC is very poor, and treatment of the advanced form is still problematic. In this article, we review the clinical efficacy and toxicity of enteric-coated tegafur/uracil in the treatment of patients with advanced non-resectable HCC.

Formulation Optimization Utilizing D-Optimal Experimental Design of Oral Capsules Containing Enteric-Coated Pellets of Lansoprazole and<i>in vivo </i>Bioequivalence

An optimized formulation of capsules containing Lansoprazole enteric-coated pellets using D-Optimal design with a polynomial statistical model were prepared by using Eudragit?L100 as an enteric coated polymer to provide resistance to simulated gastric acid dissolution in buffer media. D-Optimal experimental design was used to determine the optimal level for three coating layers that were applied to formulate the enteric-coated pellets including a drug loading layer, a sub-coating, and an outer enteric coating. Dissolution studies were performed on the prepared Lansoprazole capsules. Less than 5 percent of Lansoprazole was released in 60 minutes in an acidic dissolution medium (pH 1.2) and greater than 90 percent of active ingredient was released in the next 60 minutes in a buffer dissolution medium (pH 6.8). The Lansoprazole capsules were stable with no observable change in physico-chemical properties in accelerated and normal storage conditions for 6 and 18 months, respectively. The pharmacokinetic parameters Cmax, Tmax, AUC0-t, and AUC0-∞ were determined after administration of the D-Optimal design optimized capsules of LPZ to healthy beagle dogs and were statistically compared to Gastevin? capsules as a reference (KRKA, Slovenia) using the non-compartmental method with the aid of WinNonlin 5.2 software. The analysis of variance showed that the two formulations did not demonstrate bioequivalence using a 90% confidence interval range (80% - 120%) of Cmax, AUC0-t, and AUC0-∞. No significant difference in Tmax was found at the 0.95 significance level using the Wilcoxon signed-rank test. D-Optimal Experimental Design provided definitive direction for an optimal formulation of capsules containing enteric-coated pellets of lansoprazole loaded within the coating of pellets that provided similar bioequivalence to Gastevin.

Pharmacokinetic Evaluation of Chitosan-Succinyl-Prednisolone Conjugate Microparticles as a Colonic Delivery System: Comparison with Enteric-Coated Conjugate Microparticles

In the previous study, chitosan-succinyl-prednisolone conjugate microparticles (MP) were found to exhibit good efficacy and reduced toxicity nearly as well as their Eudragit L-coated microparticles (MP/EuL). This proposes a question whether enteric-coating of MP is necessary or not. Although MP/EuL were already examined for their pharmacokinetic and gastrointestinal behaviors, MP have not been done yet. Therefore, in this study, MP were evaluated by investigating pharmacokinetic features in detail. MP with the in vitro features equivalent to those of the previous conjugate microparticles could be produced more readily in the modified preparative method. Pharmacokinetic and gastrointestinal behaviors of MP were investigated by intragastric dosing (5 mg PD eq./kg) to rats with 2,4,6-trinitrobenzenesulfonic acid-induced ulcerative colitis. The plasma concentration was suppressed extensively in MP as well as MP/EuL, supporting the reduction of PD systemic toxic side effects. However, the plasma level increased gradually up to 7 h in MP, but not in MP/EuL. At 8 h after dosing, MP were detected in the stomach to a fair extent, and free PD was found there, indicating that MP were subjected to trapping in the stomach probably due to positive charge of chitosan molecules. For MP, such prolonged localization and slow release of PD in the stomach were probably associated with the gradual increase in plasma concentration. Therefore, MP/EuL were evaluated to be superior to MP for effective targeting to ulcerative colitis. It is concluded that enteric-coating is very important for the targeting system using MP.

Influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction

Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.

米曲菌胰酶片联合雷贝拉唑与莫沙必利治疗反流性食管炎患者的效果

目的:探讨米曲菌胰酶片联合雷贝拉唑、莫沙必利治疗反流性食管炎患者的效果。方法:选取2022年5月至2023年5月该院收治的74例反流性食管炎患者进行前瞻性研究,按照随机数字表法将其分成对照组和观察组各37例。对照组采用雷贝拉唑联合莫沙必利治疗,观察组在对照组基础上联合米曲菌胰酶片治疗。比较两组临床疗效,治疗前后临床症状积分、血清炎性因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平,以及不良反应发生率。结果:观察组治疗总有效率为91.89%(34/37),高于对照组的72.97%(27/37),差异有统计学意义(P<0.05);治疗后,观察组烧心、反酸、嗳气、胸骨疼痛、食欲不振等临床症状积分及血清hs-CRP、TNF-α、IL-6水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:米曲菌胰酶片联合雷贝拉唑与莫沙必利治疗反流性食管炎患者能显著提高治疗总有效率,加快临床症状缓解,降低血清炎性因子水平,效果优于单用雷贝拉唑和莫沙必利。

The Synthesis and Characterization of β-cyclodextrin Derivated Pancreatin Used as Chiral Selector in Capillary Electrochromatography

The preparation of capillary electrochromatography column for chiral separation with β-cyclodextrin derivatized Pancreatin was imvestigated, which had three steps, synthesis of β-cyclodextrin derivated pancreatin, the modification of the capillary internal surface and the covalent binding of β-cyclodextrin derivated pancreatin on the capillary internal wall. β-cyclodextrin derivated pancreatin was synthesized using β-cyclodextrin and protein in the presence of ethylene glycol diglycidyl ether （EGDE） in boric acid buffer at pH = 8.7. Amino group was coated on the internal surface of the silica capillary by sot-gel technology using triethoxylmethylsiloxane and （ 3-aminopropyl ） trimethoxysiloxane. Covalent binding of β-cyclodextrin derivated pancreatin was performed by glataraldehyde. Chlorpheniramine, phenylalanine and troopine were separated baseline by β-cyclodetrin derivated pancreatin in capillary electrochromatography.

中西医结合治疗功能性消化不良的临床效果

目的:探讨清胃化浊饮联合米曲菌胰酶片治疗功能性消化不良(FD)的临床效果。方法:选取2018年6月-2019年9月于河北省中医院脾胃病三科门诊就诊的130例FD患者,将其随机分为两组,治疗组65例予清胃化浊饮及米曲菌胰酶片,对照组65例予米曲菌胰酶片,两组用药均为60 d。比较两组治疗前后功能性消化不良生存质量量表(FDDQL)、7-分整体症状量表(GOSS)评分、血清胃泌素(GAS)、血清神经肽Y(NPY)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平、胃窦收缩频率、胃窦收缩幅度、胃半排空时间及胃窦运动指数。结果:治疗后,治疗组GOSS评分、血清GAS、IL-6、TNF-α水平均低于对照组,FDDQL评分、血清NPY水平均高于对照组(P<0.05)。治疗后,治疗组胃窦收缩频率、胃窦收缩幅度、胃窦运动指数均高于对照组,胃半排空时间短于对照组(P<0.05)。结论:应用清胃化浊饮联合米曲菌胰酶片治疗FD,能够明显改善患者症状,促进胃排空,使患者生活质量得到改善,其机制可能与提高患者血清NPY水平,降低血清GAS、IL-6、TNF-α水平有关。

弹性蛋白肽的制备工艺优化及其理化性质分析

采用牛动脉弹性蛋白为原料,以弹性蛋白酶抑制活性和蛋白回收率为评价指标,研究弹性蛋白肽制备工艺和理化性质。结果表明,胰酶在酶添加量1.0%、pH 11、温度45℃和时间15 h的条件下酶解弹性蛋白,弹性蛋白酶抑制活性(蛋白浓度为10 mg/mL)为35.63%,蛋白回收率可达80.08%;弹性蛋白酶解过程中,部分β-折叠和α-螺旋转化为β-转角,酶解产物小于1000 Da的肽段占45.50%,富含疏水性氨基酸和芳香族氨基酸,具有较强还原力,清除DPPH和ABTS自由基的IC 50值分别为6.90,3.41 mg/mL,且在温度<85℃、pH为中性和碱性的条件下具有良好的稳定性。

慢性胰腺炎患者营养不良的发病原因及诊治进展

慢性胰腺炎(chronic pancreatitis,CP)是一种持续、进展性的胰腺炎症性疾病,营养不良是CP患者较常见的临床表现,主要是由胰腺外分泌功能不全引起,也可能与胰腺内分泌功能不全、生活习惯改变有关.目前仍缺乏CP患者营养不良的诊断金标准,临床医生应通过人体测量参数、检验参数、影像学诊断、胰腺外分泌功能检测等方面进行综合评估,早期发现CP患者的营养不良,及时采取干预措施,包括改善饮食及生活习惯、肠内/肠外营养、胰酶替代疗法、抑酸药辅助治疗、调节肠道菌群、中医中药等,必要时采用内镜和外科手术治疗.

米曲菌胰酶片联合雷贝拉唑和莫沙必利治疗反流性食管炎伴功能性消化不良患者的效果

目的:观察米曲菌胰酶片联合雷贝拉唑和莫沙必利治疗反流性食管炎(RE)伴功能性消化不良(FD)患者的效果。方法:选取2020年3月至2022年3月该院收治的88例RE伴FD患者进行前瞻性研究,按照随机数字表法将其分为观察组与对照组各44例。对照组给予雷贝拉唑钠肠溶片联合枸橼酸莫沙必利片治疗,观察组在对照组基础上给予米曲菌胰酶片治疗,比较两组疗效、症状评分、胃肠动力学指标[上食管括约肌压力(UESP)、下食管括约肌压力(LESP)、促胃动素(MTL)]水平和酸反流指标(酸暴露时间、酸反流次数)水平。结果:观察组治疗总有效率为95.45%,明显高于对照组的77.27%,差异有统计学意义(P<0.05);治疗后,两组反酸、胸骨后疼痛症状评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组UESP、LESP和MTL水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组酸暴露时间均短于治疗前,且观察组短于对照组,两组酸反流次数均少于治疗前,且观察组少于对照组,差异有统计学意义(P<0.05)。结论:米曲菌胰酶片联合雷贝拉唑和莫沙必利治疗RE伴FD患者可提高治疗总有效率和胃肠动力学指标水平,降低症状评分,缩短酸暴露时间,以及减少酸反流次数,效果优于雷贝拉唑联合莫沙必利治疗。

曲美布汀联合米曲菌胰酶片治疗功能性消化不良的疗效及对患者肠道菌群和胃肠动力的影响

目的 研究曲美布汀联合米曲菌胰酶片治疗功能性消化不良(FD)的疗效及对患者肠道菌群和胃肠动力的影响。方法 采用随机数字表法将该院2021年1月至2023年2月收治的84例功能性消化不良患者分为对照组(42例)、研究组(42例)。对照组给予曲美布汀治疗,研究组给予曲美布汀联合米曲菌胰酶片治疗。比较两组疗效、不良反应发生率;比较两组治疗前后临床症状、胃肠动力[胃窦收缩次数(FB)、胃体蠕动次数(FA)、胃排空率(GER)]、胃容受性(GA)、肠道菌群数量,以及血清蛋白酶激活受体2蛋白(PAR2)、水通道蛋白3(AQP3)、胃动素(MOT)、分泌型卷曲相关蛋白1(SFRP1)水平差异。结果 研究组临床总有效率(92.86%)高于对照组(73.81%),差异有统计学意义(P<0.05)。治疗前两组嗳气、食欲不振、腹胀腹痛、早饱症状评分比较,差异均无统计学意义(P>0.05);治疗后研究组嗳气、食欲不振、腹胀腹痛、早饱症状评分低于对照组(P<0.05)。治疗前两组FA、FB、GER、GA比较,差异均无统计学意义(P>0.05);治疗后研究组FA、FB、GER、GA高于对照组(P<0.05)。治疗前两组肠杆菌、乳酸杆菌、双歧杆菌、肠球菌数量比较,差异均无统计学意义(P>0.05);治疗后研究组肠杆菌、肠球菌数量低于对照组,乳酸杆菌、双歧杆菌数量高于对照组,差异均有统计学意义(P<0.05)。治疗后研究组MOT水平高于对照组,PAR2、AQP3、SFRP1水平低于对照组,差异均有统计学意义(P<0.05)。研究组不良反应总发生率(4.76%)与对照组(7.14%)相比,差异无统计学意义(P>0.05)。结论 曲美布汀联合米曲菌胰酶片治疗FD效果显著,能提高患者胃肠动力、GA,改善患者肠道菌群及临床症状。

HPLC法测定复方胰酶片中猪去氧胆酸和鹅去氧胆酸的含量

目的建立高效液相色谱法测定复方胰酶片中猪去氧胆酸和鹅去氧胆酸的含量。方法采用SunShell HFC_(18~30)色谱柱(100mm×4.6mm,2.6μm),流动相为乙腈-水-磷酸(35∶65∶0.1),检测波长为192nm,柱温为40℃,流速1.0 ml/min。结果猪去氧胆酸和鹅去氧胆酸在所考察的浓度范围内的峰面积与浓度呈良好的线性关系,相关系数分别为0.9999和0.9998;平均加样回收率分别为76.6%[相对标准偏差(RSD)为4.5%]和91.4%(RSD为1.9%)。结论此方法准确、灵敏,可用于复方胰酶片中猪去氧胆酸和鹅去氧胆酸的测定。

胰酶肠溶胶囊治疗慢性胰腺炎伴胰腺外分泌不足的临床效果分析

目的:探究慢性胰腺炎伴胰腺外分泌不足患者应用胰酶肠溶胶囊的临床效果。方法:选取2019年5月—2023年5月武威市第二人民医院收治的80例慢性胰腺炎伴胰腺外分泌不足患者作为研究对象,采用随机数字表法分成两组,各40例。参照组实施常规药物治疗,试验组实施常规药物联合胰酶肠溶胶囊治疗。对比两组患者临床疗效、临床症状积分及粪便特征。结果:试验组治疗有效率高于参照组,差异有统计学意义(P=0.034)。治疗后,试验组腹部不适、嗳气、食欲不振及恶心症状积分均低于参照组,差异有统计学意义(P<0.001)。治疗后,试验组大便质量、粪便脂肪量、粪便含氮量小于参照组,排便频率均少于参照组,差异有统计学意义(P<0.001)。结论:胰酶肠溶胶囊治疗慢性胰腺炎伴胰腺外分泌不足的临床效果显著,可减轻患者临床症状,增强消化能力。

西尼必利联合米曲菌胰酶片治疗功能性消化不良及对患者胃肠动力指标的影响

目的研究西尼必利联合米曲菌胰酶片治疗功能性消化不良的效果。方法选择2022年12月—2023年7月本院收治的57例功能性消化不良患者为研究对象,依照随机数表法分成对照组(29例)和研究组(28例),对照组应用米曲菌胰酶片治疗,研究组应用西尼必利联合米曲菌胰酶片治疗,对比两组患者临床疗效。结果治疗后,研究组各项指标均优于对照组(P<0.05)。两组患者不良反应发生率对比无显著差异(P>0.05)。结论西尼必利联合米曲菌胰酶片治疗可有效强化临床疗效,减少用药不良反应,值得作为主要用药方案在临床广泛推广。

胰酶胶囊与多酶片治疗胰腺炎伴消化不良症状的疗效比较

目的 :比较胰酶胶囊与多酶片治疗胰腺炎伴消化不良病人的疗效。方法 :将 63例病人随机分成 2组 ,胰酶胶囊组 33例给予胰酶胶囊 2粒 ,po ,tid× 4wk ;多酶片组 30例给予多酶片 5片 ,po ,tid× 4wk ;服药后 2 ,4wk进行临床症状的积分评价。结果 :胰酶胶囊组治疗 2wk后在腹痛、饱胀、胃肠胀气、腹泻等积分分别下降了 (0 .86± 0 .13)分 ,(1.33± 0 .14 )分 ,(1.4 0± 0 .2 1)分 ,(0 .90± 0 .16)分 ;多酶片组分别下降了 (0 .13± 0 .0 3)分 ,(0 .37±0 .0 4 )分 ,(0 .36± 0 .0 7)分 ,(0 .15± 0 .0 4 )分。均P<0 .0 1。治疗后 4wk胰酶胶囊组总有效率为94 %、多酶片组为 5 7% ,2组间比较P <0 .0 5。结论

胰酶制备新工艺的研究

目的研究从猪胰腺中提取胰酶的新工艺.方法使用φ=7.5%异丙醇为提取溶剂,添加ρ=0.2% CaCl2和φ=1%胰酶粉为激活剂以及适量的保护剂,并加入NaHCO3使体系的pH稳定在6.5～7.0之间,在室温下提取3 h.结果在优化工艺条件下,制得的胰酶制品中的胰蛋白酶、胰淀粉酶、胰脂肪酶的酶活力分别达5 200、 57 300、 37 000 u/g以上,为中国药典所规定的最低酶活的8～10倍,收率10%～12%.结论该工艺简单、提取效率高、产品酶活高.

牛奶大分子蛋白的水解及其抗原性变化

目的 :将婴儿乳粉以不同的食品级蛋白酶水解 ,降低牛奶的分子量 ,考察牛奶酶水解产物过敏原性的变化。方法 :采用胃蛋白酶、胰蛋白酶和自制胰酶制品对婴儿奶粉进行酶解 ,以快速蛋白质液相色谱测得酶解产物分子量分布和所占比例。通过实验动物主动、被动皮肤反应和口服致敏肠腔通透性变化观察不同酶水解后牛奶的过敏原性变化。结果 :快速蛋白质液相色谱结果表明蛋白酶水解牛奶后 ,牛奶蛋白分子量明显降低 ,尤以自制胰酶对乳粉的水解程度最高 (分子量 <10 0 0占 92 % ;10 0 0～10 0 0 0占 8% )。胃蛋白酶、胰蛋白酶和胰酶水解产物可以显著抑制由牛奶蛋白引起的小鼠耳速发型主动皮肤过敏 ,抑制率分别为 5 1%、83%和 86 %。小鼠同种及异种被动皮肤过敏反应实验中 ,与未水解奶粉组比较 ,同种皮肤过敏反应三种酶解产物炎性渗出降低率分别为 2 9%、70 %和 82 % ,异种皮肤过敏反应的降低率分别为 34%、70 %和 82 %。口服致敏小鼠肠腔通透性及分泌功能测定结果显示 ,胰酶水解产物致敏小鼠的肠腔伊文思蓝渗出率比未水解前降低了 2 7%。结论 :酶水解后牛奶大分子蛋白物质降解 ,其过敏原性有不同程度的降低 ,尤以胰酶水解产物变化最为显著。